Novo­gen boss re­signs

Townsville Bulletin - - NEWS -

PHARMA CEU­TI­CALS com­pany Novo­gen has lost a pi­o­neer in an­ti­cancer drugs with the sud­den res­ig­na­tion of its chief ex­ec­u­tive and founder Dr Graham Kelly.

Dr Kelly will re­sume his work in non- on­col­ogy- based re­search af­ter re­sign­ing yesterday, ef­fec­tive im­me­di­ately, caus­ing the com­pany’s share price to drop 2c, or 8.51 per cent, to 21.5c at 1401 AEST.

“I am sat­is­fied I am leav­ing the com­pany in a very sound po­si­tion,” Dr Kelly said in a state­ment.

“The com­pany is well placed now to pro­ceed into the clinic with its three on­col­ogy drug can­di­dates.

“My par­tic­u­lar in­ter­est and skills are in early- stage drug de­vel­op­ment and I now want to fo­cus on that.”

Dr Kelly, a prostate can­cer suf­ferer him­self who has ex­pressed a de­sire see anti- can­cer drugs pro­vided to fam­i­lies at an af­ford­able price, left the com­pany in 2005 af­ter found­ing it in 1994, and re­joined in 2012.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.